Independent study demonstrates amyloid probability score accurately indicates amyloid pathology

Ilana Fogelman, Tim West, Joel B. Braunstein, Philip B. Verghese, Kristopher M. Kirmess, Matthew R. Meyer, John H. Contois, Eli Shobin, Kyle L. Ferber, Jake Gagnon, Carrie E. Rubel, Danielle Graham, Randall J. Bateman, David M. Holtzman, Shuguang Huang, Joanne Yu, Sha Yang, Kevin E. Yarasheski

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: The amyloid probability score (APS) is the model read-out of the analytically validated mass spectrometry-based PrecivityAD® blood test that incorporates the plasma Aβ42/40 ratio, ApoE proteotype, and age to identify the likelihood of brain amyloid plaques among cognitively impaired individuals being evaluated for Alzheimer's disease. Purpose: This study aimed to provide additional independent evidence that the pre-established APS algorithm, along with its cutoff values, discriminates between amyloid positive and negative individuals. Methods: The diagnostic performance of the PrecivityAD test was analyzed in a cohort of 200 nonrandomly selected Australian Imaging, Biomarker & Lifestyle Flagship Study of Aging (AIBL) study participants, who were either cognitively impaired or healthy controls, and for whom a blood sample and amyloid PET imaging were available. Results: In a subset of the dataset aligned with the Intended Use population (patients aged 60 and older with CDR ≥0.5), the pre-established APS algorithm predicted amyloid PET with a sensitivity of 84.9% (CI: 72.9–92.1%) and specificity of 96% (CI: 80.5–99.3%), exclusive of 13 individuals for whom the test was inconclusive. Interpretation: The study shows individuals with a high APS are more likely than those with a low APS to have abnormal amounts of amyloid plaques and be on an amyloid accumulation trajectory, a dynamic and evolving process characteristic of progressive AD pathology. Exploratory data suggest APS retains its diagnostic performance in healthy individuals, supporting further screening studies in the cognitively unimpaired.

Original languageEnglish
Pages (from-to)765-778
Number of pages14
JournalAnnals of Clinical and Translational Neurology
Issue number5
StatePublished - May 2023


Dive into the research topics of 'Independent study demonstrates amyloid probability score accurately indicates amyloid pathology'. Together they form a unique fingerprint.

Cite this